Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
About this item
Full title
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2017-09, Vol.377 (13), p.1217-1227
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this trial involving patients with atherosclerotic disease who were receiving effective statin therapy, those who were assigned to receive anacetrapib, a CETP inhibitor, had a lower risk of major coronary events than did those in the placebo group.
Alternative Titles
Full title
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1943789534
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1943789534
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1706444
